Skip to main content

Share story

Science

Progress 94 cargo spacecraft launches to ISS

The Progress 94 cargo spacecraft launches to the International Space Station on March 22, 2026. Image: Primary
The unpiloted Roscosmos Progress 94 spacecraft launched on a Soyuz rocket from the Baikonur Cosmodrome in Kazakhstan. Liftoff took place at 7:59 a.m. EDT, or 4:59 p.m. Baikonur time. The spacecraft is now safely in orbit and headed to the International Space Station. One of the Progress 94's two KURS automated rendezvous antennas did not deploy as planned after launch. All other systems are operating as designed. The spacecraft is scheduled to dock at 9:34 a.m. Tuesday, March 24, at the space-facing port of the station's Poisk module. Roscosmos will continue troubleshooting the antenna issue. If the antenna cannot be deployed, cosmonaut Sergey Kud-Sverchkov will manually pilot the spacecraft for rendezvous and docking using the TORU system in the Zvezda Service Module. The spacecraft is delivering about three tons of food, fuel, and supplies to the station crew. NASA will provide live coverage of the rendezvous and docking beginning at 8:45 a.m. on NASA+, Amazon Prime, and the agency's YouTube channel.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from NASA and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.